Gene-Disorder Association · Article
Gene
FGFR3 Fibroblast Growth Factor Receptor 3
×
First reported
1950
Supporting publications
3
Approved treatment annotated
Association Review
In brief The association between FGFR3 (Fibroblast Growth Factor Receptor 3) and Cervix Carcinoma is supported by expert-curated evidence, drawing on a single expert-curated source, which records pathogenic variants.
Sources
1
Clinical variants
35
Symptoms
0
Compounds
1
Trials
2 of 2,668 via FGFR3 compounds
Publications
3
Contents
01
At a glance
Association overview A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
Request access
02
Provenance
Evidence and sources 1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
Request access
3 source summaries
A gene summary alongside the source descriptions it was distilled from.
Request access
04
Cervix Carcinoma
The disorder 7 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
Request access
05
ClinVar and variant evidence
Genetic basis 35 clinical variants
ClinVar variants reported for this pair, with disorder-specific significance, review status, molecular consequence and origin.
Request access
06
Interventions
Therapeutics 1 compound or drug
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
Request access
07
Human studies
Clinical trials 2,668 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
Request access
3 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
Request access
09
Provenance
References & sources 9 references
Every source and publication cited across this dossier, as one numbered reference list.
Request access